MiniMed (MMED) EBITDA Margin (2025 - 2026)
MiniMed (MMED) posted EBITDA Margin of 11.11% for Q2 2026, up 12.22% on a QoQ basis from 12.66% in Q1 2026, and up 933.0% year-over-year from 1.08% in Q2 2025.
MiniMed (MMED) EBITDA Margin (2025 - 2026) Analysis & Trends
MiniMed's EBITDA Margin history runs 2 years deep, the most recent figure standing at 11.11% for Q2 2026.
- Quarterly EBITDA Margin rose 933.0% year-over-year to 11.11% in Q2 2026, while the trailing twelve-month figure through Apr 2026 was 10.53% (changed N/A YoY) and the FY2026 annual result came in at 6.13%, down 75.0% from the prior year.
- EBITDA Margin was 11.11% for Q2 2026 at MiniMed, up from 12.66% in the prior quarter.
- Across five years, EBITDA Margin topped out at 3.06% in Q1 2025 and bottomed at 20.44% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Veeva Systems | 31.81 Bn | 24.49 Bn | 662.02 Mn | 30.93% |
| 2 | BrightSpring Health Services | 14.76 Bn | 13.86 Bn | 482.22 Mn | 3.36% |
| 3 | Healthequity | 8.36 Bn | 8.10 Bn | 256.31 Mn | 29.03% |
| 4 | Hinge Health | 5.91 Bn | 5.60 Bn | 154.23 Mn | 17.59% |
| 5 | 10x Genomics | 5.89 Bn | 5.35 Bn | 106.18 Mn | -11.30% |
| 6 | MiniMed | 4.45 Bn | 4.16 Bn | 480.00 Mn | -11.11% |
| 7 | Waystar Holding | 4.41 Bn | 4.35 Bn | 216.84 Mn | 25.64% |
| 8 | Doximity | 3.93 Bn | 3.18 Bn | 125.97 Mn | 17.08% |
| 9 | Privia Health | 3.10 Bn | 2.68 Bn | - | 1.23% |
| 10 | Omnicell | 1.89 Bn | 1.65 Bn | 140.36 Mn | 5.44% |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 24, 2026 | -11.11% |
| Jan 23, 2026 | -12.66% |
| Apr 25, 2025 | -20.44% |
| Jan 24, 2025 | 3.06% |